EGFR and colorectal carcinoma: For example, unlike in PDAC, KRASG12C inhibition in NSCLC and CRC tumors leads to upstream accumulation of activated EGFR and other ERBB receptor family members, eventually leading to escape from the KRASG12C inhibitor.235–237 Accordingly, the coinhibition of upstream and/or downstream activators has been heavily explored.